Optimization of a series of quinazolinone-derived antagonists of CXCR3

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 17, 2009, Pages 5114-5118

  Liu, Jiwen ^a   Fu, Zice ^a   Li, An Rong ^a   Johnson, Michael ^a   Zhu, Liusheng ^a   Marcus, Andrew ^a   Danao, Jay ^a   Sullivan, Tim ^a   Tonn, George ^a   Collins, Tassie ^a   Medina, Julio ^a  

^a AMGEN INC   (United States)

Author keywords

Antagonist; Chemokine receptor; CXCL10; CXCL11; CXCL9; CXCR3; GPCR; IP10; ITAC; MIG; Quinazolinone; SAR

Indexed keywords

3,3,3 TRIFLUOROETHOXY DERIVATIVE; AMG 487; BLEOMYCIN; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; FUNCTIONAL GROUP; PHENYLENEDIAMINE; PYRIDINE CARBOXYLIC ACID; QUINAZOLINONE DERIVATIVE; REAGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CHEMICAL REACTION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; SUBSTITUTION REACTION;

ACETAMIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL MOVEMENT; DOGS; HAPLORHINI; HUMANS; MICE; PYRIMIDINONES; QUINAZOLINONES; RATS; RECEPTORS, CXCR3; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 68349155551     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.032     Document Type: Article

References (34)

1. Medina J., Johnson M.G., and Collins T.L. Ann. Rep. Med. Chem. 40 (2005) 215
2. Collins T.L., Johnson M.G., and Medina J.C. In: Neote K., Letts G.L., and Moser B. (Eds). Chemokine Biology-Basic Research and Clinical Application Vol. II (2007), Birkhauser 79
3. Yuan Y.H., ten Hove T., The F.O., Slors J.F., van Deventer S.J., and te Velde A.A. Inflamm. Bowel Dis. 7 (2001) 281
4. Uguccioni M., Gionchetti P., Robbiani D.F., Rizzello F., Peruzzo S., Campieri M., and Baggiolini M. Am. J. Pathol. 155 (1999) 331-336
5. Mahad D.J., Howell S.J., and Woodroofe M.N. J. Neurol. Neurosurg. Psychiatry 72 (2002) 498
6. Mahad D.J., Lawry J., Howell S.J., and Woodroofe M.N. Mult Scler. 9 (2003) 189
7. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., Qin S., Rottman J., Sellebjerg F., Strieter R.M., Frederiksen J.L., and Ransohoff R.M. J. Clin. Invest. 103 (1999) 807
8. Sorensen T.L., Trebst C., Kivisakk P., Klaege K.L., Majmudar A., Ravid R., Lassmann H., Olsen D.B., Strieter R.M., Ransohoff R.M., and Sellebjerg F. J. Neuroimmunol. 127 (2002) 59
9. Gottlieb A.B., Luster A.D., Posnett D.N., and Carter D.M. J. Exp. Med. 68 (1988) 941
10. Rottman J.B., Smith T.L., Ganley K.G., Kikuchi T., and Krueger J.G. Lab Invest. 81 (2001) 335
11. Patel D.D., Zachariah J.P., and Whichard L.P. Clin. Immunol. 98 (2001) 39
12. Melter M., Exeni A., Reinders M.E., Fang J.C., McMahon G., Ganz P., Hancock W.W., and Briscoe D.M. Circulation 104 (2001) 2558
13. Segerer S., Cui Y., Eitner F., Goodpaster T., Hudkins K.L., Mack M., Cartron J.P., Colin Y., Schlondorff D., and Alpers C.E. Am. J. Kidney Dis. 37 (2001) 518
14. Agostini C., Calabrese F., Rea F., Facco M., Tosoni A., Loy M., Binotto G., Valente M., Trentin L., and Semenzato G. Am. J. Pathol. 158 (2001) 1703
15. Rosenblum J.M., Zhang Q.W., Siu G., Collins T., Sullivan T., Dairaghi D., Medina J., and Fairchild R.L. Transplantation 87 (2009) 360
16. Cameron C.M., Cameron M.J., Bermejo-Martin J.F., Ran L., Xu L., Turner P.V., Ran R., Danesh A., Fang Y., Chan P.M., Mytle N., Sullivan T., Collins T., Johnson M., Medina J., Rowe T., and Kelvin D.J. J. Virol. 82 (2008) 11308
17. Walser T.C., Rifat S., Ma X., Kundu N., Ward C., Goloubeva O., Johnson M., Medina J., Collins T., and Fulton A.M. Cancer Res. 66 (2006) 7701
18. Johnson M., Li A., Liu J., Fu Z., Zhu L., Miao S., Wang X., Xu Q., Huang A., Marcus A., Xu F., Ebsworth K., Sablan E., Danao J., Kumer J., Dairaghi D., Lawrence C., Sullivan T., Tonn G., Schall T., Collins T., and Medina J. Bioorg. Med. Chem. Lett. 17 (2007) 3339
19. Allen D.R., Bolt A., Chapman G.A., Knight R.L., Meissner J.W.G., Owen D.A., and Watson R.J. Bioorg. Med. Chem. Lett. 17 (2007) 697
20. Storelli S., Verzijil D., Al-Badie J., Elders N., Bosch L., Timmerman H., Smit M.J., De Esch I.J.P., and Leurs R. Arch. Pharm. 340 (2007) 281
21. Cole A.G., Stroke I.L., Brescia M.R., Simhadri S., Zhang J.J., Hussain Z., Snider M., Haskell C., Ribeiro S., Appell K.C., Henderson I., and Webb M.L. Bioorg. Med. Chem. Lett. 16 (2006) 200
22. Wang Y., Busch-Petersen J., Wang F., Kiesow T.J., Graybill T.L., Jin J., Yang Z., Foley J.J., Hunsberger G.E., Schmidt D.B., Sarau H.M., Capper-Spudich E.A., Wu Z., Fisher L.S., McQueney M.S., Rivero R.A., and Widdowson L.K. Bioorg. Med. Chem. Lett. 19 (2009) 114
23. Bongartz J.-P., Buntinx M., Coesemans E., Hermans B., Van Lommen G., and Van Wauwe J. Bioorg. Med. Chem. Lett. 18 (2008) 5819
24. Hayes M.E., Breinlinger E.C., Wallace G.A., Grongsaard P., Miao W., McPherson M.J., Stoffel R.H., Green D.W., and Roth G.P. Bioorg. Med. Chem. Lett. 18 (2008) 2414
25. Hayes M.E., Wallace G.A., Grongsaard P., Bischoff A., George D.M., Miao W., McPherson M.J., Stoffel R.H., Green D.W., and Roth G.P. Bioorg. Med. Chem. Lett. 18 (2008) 1573
26. Knight R.L., Allen D.R., Birch H.L., Chapman G.A., Galvin F.C., Jopling L.A., Lock C.J., Meissner J.W.G., Owen D.A., Raphy G., Watson R.J., and Williams S.C. Bioorg. Med. Chem. Lett. 18 (2008) 629
27. Watson R.J., Allen D.R., Birch H.L., Chapman G.A., Galvin F.C., Jopling L.A., Knight R.L., Meier D., Oliver K., Meissner J.W.G., Owen D.A., Thomas E.J., Tremayne N., and Williams S.C. Bioorg. Med. Chem. Lett. 18 (2008) 147
28. Tonn G., Wong S., Wong S., Johnson M., Ma J., Cho R., Floren L., Kersey K., Berry K., Marcus A., Wang X., Van Lengerich B., Medina J., Pearson P., and Wong B. Drug Metab. Dispos. 37 (2009) 502
29. Bentz E., Moloney M.G., and Westaway S.M. Tetrahedron Lett. 45 (2004) 7395
30. 125I]-IP10 binding assay in buffer with the exception that EDTA-anti-coagulated human plasma (from frozen stocks) was used instead of the RPMI buffer. ITAC in vitro cell migration assay: 100 ng/ml of ITAC was used in the presence of 100% human plasma. Compounds were measured by their ability to inhibit CXCR3 mediated cell migration in response to ITAC.
31. Hagmann W.K. J. Med. Chem. 51 (2008) 4359
32. Muller K., Faeh C., and Diederich F. Science 317 (2007) 1881
33. Jiang D., Liang J., Hodge J., Lu B., Zhu Z., Yu S., Fan J., Gao Y., Yin Z., Homer R., Gerard C., and Noble P.W. J. Clin. Invest. 114 (2004) 291
34. Alzet osmotic mini-pump with a volume of 0.2 mL was implanted subcutaneously. The infusion rate was 1 μL/h. For more information, please visit http://www.alzet.com/downloads/TIM.pdf.